2. Search Result
Search Result
Results for "

HDAC Inhibitor

" in MedChemExpress (MCE) Product Catalog:

750

Inhibitors & Agonists

2

Screening Libraries

7

Fluorescent Dye

8

Biochemical Assay Reagents

10

Peptides

40

Natural
Products

26

Isotope-Labeled Compounds

9

Click Chemistry

1

Oligonucleotides

4

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10221
    Vorinostat
    155+ Cited Publications

    SAHA; Suberoylanilide hydroxamic acid

    		 HDAC Autophagy Mitophagy Filovirus Apoptosis HPV Infection Cancer
    Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV), with ID50 values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis . Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification .
    Vorinostat
  • HY-12163
    Entinostat
    85+ Cited Publications

    MS-275; SNDX-275

    		 HDAC Autophagy Apoptosis Cancer
    Entinostat is an oral and selective class I HDAC inhibitor, with IC50s of 243 nM, 453 nM, and 248 nM for HDAC1, HDAC2, and HDAC3, respectively.
    Entinostat
  • HY-12164
    Mocetinostat
    20+ Cited Publications

    MGCD0103

    		 HDAC Autophagy Apoptosis Cancer
    Mocetinostat (MGCD0103) is a potent, orally active and isotype-selective HDAC (Class I/IV) inhibitor with IC50s of 0.15, 0.29, 1.66 and 0.59 μM for HDAC1, HDAC2, HDAC3 and HDAC11, respectively. Mocetinostat shows no inhibition on HDAC4, HDAC5, HDAC6, HDAC7, or HDAC8.
    Mocetinostat
  • HY-18998
    LMK-235
    25+ Cited Publications

    		 HDAC Cancer
    LMK-235 is a potent and selective HDAC4/5 inhibitor, inhibits HDAC5, HDAC4, HDAC6, HDAC1, HDAC2, HDAC11 and HDAC8, with IC50s of 4.22 nM, 11.9 nM, 55.7 nM, 320 nM, 881 nM, 852 nM and 1278 nM, respectively, and is used in cancer research.
    LMK-235
  • HY-18361
    TMP195
    15+ Cited Publications

    		 HDAC Cancer
    TMP195 is a selective class IIa histone deacetylase (HDAC) inhibitor with Kis of 59, 60, 26, 15 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.
    TMP195
  • HY-16425
    RG2833
    10+ Cited Publications

    RGFP109

    		 HDAC Cancer
    RG2833 is a brain-penetrant HDAC inhibitor with IC50s of 60 nM and 50 nM for HDAC1 and HDAC3, respectively. The Ki values for HDAC1 and HDAC3 are 32 and 5 nM, respectively .
    RG2833
  • HY-18613
    CAY10603
    5+ Cited Publications

    BML-281

    		 HDAC Cancer
    CAY10603 (BML-281) is a potent and selective HDAC6 inhibitor, with an IC50 of 2 pM; CAY10603 (BML-281) also inhibits HDAC1, HDAC2, HDAC3, HDAC8, HDAC10, with IC50s of 271, 252, 0.42, 6851, 90.7 nM.
    CAY10603
  • HY-19772
    GSK3117391

    ESM-HDAC391; CHR-5154; HDAC-IN-3

    		 HDAC c-Fms Inflammation/Immunology
    GSK3117391 (ESM-HDAC391; CHR-5154; HDAC-IN-3) is an orally active HDAC inhibitor with a IC50 of 55 nM. Using esterase-sensitive motif technology, GSK3117391 is selectively converted into its active acid metabolite HDAC189 in cells expressing carboxylesterase-1. GSK3117391 induces sustained global protein acetylation in monocytes, inhibits the production of proinflammatory cytokines, depletes circulating monocytes, downregulates the expression of CSF1R, and inhibits monocyte adhesion and differentiation. GSK3117391 can be used in the research of chronic inflammatory diseases .
    GSK3117391
  • HY-18700
    BRD73954
    4 Publications Verification

    		 HDAC Cancer
    BRD73954 is a potent HDAC inhibitor and selectively inhibiting both HDAC6 and HDAC8 with IC50 values of 0.0036, 0.12, 9, 12, 23 µM for HDAC6, HDAC8, HDAC2, HDAC1 and HDAC3, respectively. BRD73954 decreases the levels of HDAC6, associated with upregulation of Ac-Tubulin .
    BRD73954
  • HY-101780
    Tinostamustine
    4 Publications Verification

    EDO-S101; NL-101

    		 HDAC Cancer
    Tinostamustine (EDO-S101) is a pan HDAC inhibitor; inhibits HDAC6, HDAC1, HDAC2 and HDAC3 with IC50 values of 6 nM, 9 nM, 9 nM and 25 nM, respectively .
    Tinostamustine
  • HY-169259
    HDAC9-IN-1

    		HDAC DNA/RNA Synthesis Reactive Oxygen Species (ROS) Apoptosis Caspase p38 MAPK Cancer
    HDAC9-IN-1 is a selective class IIa HDAC inhibitor that binds to HDAC9 with an IC50 of 40 nM. HDAC9-IN-1 potently inhibits HDACs 4 and 7 while showing weak activity against HDAC6 (IC50 values: 180 nM (HDAC4), 190 nM (HDAC7), 970 nM (HDAC6)). HDAC9-IN-1 significantly inhibits several human cancer cells, induces apoptosis and DNA damage in human cancer cells, and modulates caspase-related proteins and p38 in human cancer cells. HDAC9-IN-1 can be used for the research of oral cancer, breast cancer, gastric cancer .
    HDAC9-IN-1
  • HY-111342
    HDAC8-IN-1
    4 Publications Verification

    		 HDAC Cancer
    HDAC8-IN-1 is a HDAC8 inhibitor with an IC50 of 27.2 nM.
    HDAC8-IN-1
  • HY-130493
    HPB

    HDAC6 Inhibitor HPB

    		 HDAC Cancer
    HPB (HDAC6 inhibitor HPB) is a selective HDAC6 inhibitor with an IC50 of 31 nM. HPB exhibits >30-flod selectivity for HDAC6 over HDAC1 .
    HPB
  • HY-13592
    HDAC-IN-7

    Chidamide impurity

    		 HDAC Cancer
    HDAC-IN-7 (Chidamide impurity) is an impurity of Chidamide. Chidamide is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor.
    HDAC-IN-7
  • HY-144893
    OKI-006

    		HDAC Cancer
    OKI-006 is an orally active histone deacetylase (HDAC) inhibitor. OKI-006 is the active metabolite of OKI-005 (HY-185584) and OKI-179 (HY-156602). OKI-006 can be used for the research of cancers such as breast cancer and colorectal cancer .
    OKI-006
  • HY-172157
    HDAC11-IN-2

    		HDAC AMPK Metabolic Disease
    HDAC11-IN-2 (compound B6) is a high selective Histone Deacetylase 11 (HDAC11) inhibitor. HDAC11-IN-2 inhibits HDAC11 and HDAC8 with IC50s of 51.1 ×10 -3 μM and 5 μM, respectively. HDAC11-IN-2 inhibits denovolipogenesis (DNL) and promotes fatty acid oxidation, thus mitigating hepaticlipid accumulation and pathological symptoms in MASLD mice. HDAC11-IN-2 enhances the phosphorylation of AMPKα1 at Thr172 through the inhibition of HDAC11, consequently modulating DNL and fatty acid oxidation in the liver .
    HDAC11-IN-2
  • HY-156274
    HDAC6-IN-23

    		HDAC Cancer
    HDAC6-IN-23 (compound 9) is an orally active HDAC6 inhibitor .
    HDAC6-IN-23
  • HY-152174
    HDAC-IN-52

    		HDAC Cancer
    HDAC-IN-52 is a pyridine-containing HDAC inhibitor, with IC50s of 0.189, 0.227, 0.440 and 0.446 μM for HDAC1, HDAC2, HDAC3, and HDAC10, respectively. HDAC-IN-52 can be used for the research of cancer .
    HDAC-IN-52
  • HY-162086
    HDAC-IN-68

    		HDAC Cancer
    HDAC-IN-68 (Compound 29) is a potent HDAC inhibitor that disrupts microtubule structure and inhibits tumor growth. HDAC-IN-68 significantly inhibits class I HDACs (HDAC1, HDAC2, HDAC3) with IC50 values of 5.1, 11.5 and 8.8 nM, respectively .
    HDAC-IN-68
  • HY-161304
    HDAC6-IN-33

    		HDAC Cancer
    HDAC6-IN-33 (compound 6) is a selective and irreversible HDAC6 inhibitor with an IC50 of 193 nM. HDAC6-IN-33 shows no activity against HDAC1-4. HDAC6-IN-33 is a tight-binding HDAC6 inhibitor capable of inhibiting HDAC6 via a two-step slow-binding mechanism .
    HDAC6-IN-33
  • HY-124337
    BG48

    		HDAC Cancer
    BG48 is a potent HDAC inhibitor. BG48 inhibits the enzymatic activity of HDAC1 and HDAC2 .
    BG48
  • HY-157219
    HDAC6-IN-26

    		HDAC Cancer
    HDAC6-IN-26 (compound 23) is a potent inhibitor of HDAC6 .
    HDAC6-IN-26
  • HY-145816
    JPS016

    		PROTACs HDAC Apoptosis PINK1/Parkin Autophagy Reactive Oxygen Species (ROS) Cardiovascular Disease Cancer
    JPS016 is a class I histone deacetylase (HDAC) PROTAC inhibitor. JPS016 recruits the VHL E3 ligase (Ligands for E3 Ligase) to mediate the ubiquitination and proteasomal degradation of HDAC1, HDAC2 and HDAC3. JPS016 reduces the viability of colon cancer cells and induces Apoptosis. JPS016 activates the PINK1/Parkin mitochondrial Autophagy pathway, enhances cardiomyocyte viability, alleviates mitochondrial damage, and reduces mitochondrial ROS production in cells. JPS016 is applicable to research related to colon cancer and sepsis cardiomyopathy .
    JPS016
  • HY-139650
    HDAC1/2-IN-3

    		HDAC Cancer
    HDAC1/2-IN-3 is a HDAC1 and HDAC2 inhibitor with IC50 values 0-5 and 5-10 nM, respectively.
    HDAC1/2-IN-3
  • HY-114548
    Ebselen oxide

    		Guanylate Cyclase Infection
    Ebselen oxide, the selenone analogue of Ebselen, covalently modifies diguanylate cyclase (DGC) to inhibit c-di-GMP-receptor interactions and reduces DGC activity. Ebselen oxide also inhibits alginate production (IC50=14 μM) by Pseudomonas aeruginosa. Ebselen oxide inhibits HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9 (IC50 ranging from 0.2 to 4.7 μM) .
    Ebselen oxide
  • HY-112147
    IDO1 and HDAC1 Inhibitor

    		Indoleamine 2,3-Dioxygenase (IDO) HDAC Cancer
    IDO1 and HDAC1 Inhibitor (Compound 10) is a dual IDO1 and HDAC1 inhibitor with IC50s of 69.0 nM and 66.5 nM, respectively .
    IDO1 and HDAC1 Inhibitor
  • HY-150577
    HDAC-IN-45

    		HDAC Cancer
    HDAC-IN-45 (Compound 14) is a small molecule HDAC inhibitor and has anticancer activity, also can forms a hydrogen bond with residue Y303. HDAC-IN-45 (Compound 14) has substantial inhibitory effects towards HDAC1, 2 and 3 isoforms with IC50 values of 0.108, 0.585 and 0.563 μM respectively .
    HDAC-IN-45
  • HY-162487
    HDAC-IN-72

    		HDAC Cancer
    HDAC-IN-72 (compound 7j) is the most potent HDAC1 (IC50=0.65 μM), HDAC2 (IC50=0.78 μM), HDAC3 (IC50=1.70 μM) inhibitor and antiproliferative compound. HDAC-IN-72 can be used for breast cancer research .
    HDAC-IN-72
  • HY-161688
    HDAC-IN-73

    		Apoptosis HDAC Cancer
    HDAC-IN-73 (compound P-503) is a histone deacetylase (HDAC) inhibitor. HDAC-IN-73 shows IC50s values of 0.17, 0.49 µM for HDAC1 and HDAC6, respectively. Notably, HDAC-IN-73's inhibitory potency against HDAC6 is heightened, exhibiting a 9-fold greater efficacy than PsA (HY-N2150) (IC50=3.9 μM). HDAC-IN-73 shows potent antiproliferative activity, induces apoptosis, and causes cell cycle arrest at G2 / M phase. HDAC-IN-73 has the potential to be used for the research of cancer such as colon cancer .
    HDAC-IN-73
  • HY-175857
    HDAC-IN-92

    		HDAC Apoptosis Cancer
    HDAC-IN-92 is a pan-HDAC inhibitor with an IC50 of 12.58 µM in A2780 cells. HDAC-IN-92 demonstrates broad-spectrum, notable cytotoxic activity against a range of human cancer cell lines, including ovarian, liver, and breast carcinomas. HDAC-IN-92 causes apoptosis and demonstrates a notable decrease in tumor cell colony formation. HDAC-IN-92 inhibits the formation of blood vessels in the chick chorioallantoic membrane (CAM). HDAC-IN-92 exhibits anti-tumor effect in a 4T1 tumor-bearing mouse model. HDAC-IN-92 can be used for research targeting solid tumor .
    HDAC-IN-92
  • HY-179272
    Wee1/HDAC-IN-1

    		Wee1 HDAC Apoptosis Cancer
    Wee1/HDAC-IN-1 is a dual Wee1/HDAC inhibitor with an IC50 of 1.2 nM for Wee1 and IC50 values of 196 nM for HDAC1, 156 nM for HDAC3, and 55 nM for HDAC6. Wee1/HDAC-IN-1 exhibits strong antiproliferative activity against MV4-11 cells with an IC50 of 0.076 μM. Wee1/HDAC-IN-1 selectively binds to Wee1 and HDACs. Wee1/HDAC-IN-1 interferes with DNA damage repair pathways and induces apoptosis in MV4-11 cells. Wee1/HDAC-IN-1 Wee1/HDAC-IN-1 can be used for the research of acute myeloid leukemia (AML) .
    Wee1/HDAC-IN-1
  • HY-151261
    HDAC6-IN-13

    		HDAC Inflammation/Immunology
    HDAC6-IN-13 (Compound 35m) is a potent, highly selective, orally active HDAC6 inhibitor with an IC50 of 0.019 μM. HDAC6-IN-13 also inhibits HDAC1, HDAC2 and HDAC3 with IC50s of 1.53, 2.06 and 1.03 μM, respectively. HDAC6-IN-13 shows significant BBB permeability and anti-inflammatory activity .
    HDAC6-IN-13
  • HY-147731
    HDAC6-IN-9

    		HDAC Cancer
    HDAC6-IN-9 (compound 12c) is a potent and selective HDAC6 inhibitor with IC50 values of 11.8, 15.2, 4.2, 139.6, 21.3 nM for HDAC1,HDAC3, HDAC6, HDAC8, HDAC10, respectively. HDAC6-IN-9 shows anti-proliferative activities .
    HDAC6-IN-9
  • HY-157314
    HDAC6-IN-27

    		HDAC Parasite Infection
    HDAC6-IN-27 (compound 8C) is a HDAC inhibitor with IC50 vales of 15.9 nM 136.5 nM and 6180.2 nM for HDAC6, HDAC8 and HDAC1, respectively. HDAC6-IN-27 shows potent antiparasitic effects .
    HDAC6-IN-27
  • HY-146153
    HDAC-IN-40

    		HDAC Cancer
    HDAC-IN-40 is a potent alkoxyamide-based HDAC inhibitor with Ki values of 60 nM and 30 nM for HDAC2 and HDAC6, respectively. HDAC-IN-40 had antitumor effects .
    HDAC-IN-40
  • HY-15144B
    (S)-Trichostatin A

    (S)-TSA

    		 HDAC Cancer
    (S)-Trichostatin A ((S)-TSA) is a HDAC6-selective inhibitor with IC50s of 9.88 nM and 11.1 nM for Zebrafish HDAC6 and Human HDAC6, respectively. (S)-Trichostatin A weakly inhibits other human HDACs .
    (S)-Trichostatin A
  • HY-149372
    HDAC6-IN-17

    		HDAC Cancer
    HDAC6-IN-17 (compound 5b) is a potent HDAC6 inhibitor with IC50 values of 150 nM, 1400 nM, and 2300 nM for HDAC6, HDAC8, and HDAC4, respectively. HDAC6-IN-17 has cytotoxic activity on human cancer cell lines. HDAC6-IN-17 can be used in research of cancer .
    HDAC6-IN-17
  • HY-159172
    HDAC3-IN-4

    		HDAC Cancer
    HDAC3-IN-4 is a selective and orally active HDAC3 inhibitor with an IC50 of 89 nM. HDAC3-IN-4 induces the degradation of PD-L1 by regulating cathepsin B (CTSB) in the lysosomes, with a DC50 of 5.7 μM. HDAC3-IN-4 shows better selectivity for HDAC3 over HDAC1, HDAC6, HDAC7, and HDAC8 .
    HDAC3-IN-4
  • HY-178023
    HDAC6-IN-64

    		HDAC Cancer
    HDAC6-IN-64 (Compound 8) is a HDAC6 inhibitor with an IC50 of 11.9  nM. HDAC6-IN-64 has poor cell permeability. HDAC6-IN-64 can be used for chemotherapy of cancers like NSCLC research .
    HDAC6-IN-64
  • HY-162769
    HDAC3-IN-5

    		HDAC Apoptosis Cancer
    HDAC3-IN-5 (9c) is a HDAC3 selective inhibitor, with IC50 values of 4.2 nM, 1629 nM and 298.2 nM for HDAC3, HDAC2, HDAC1, respectively. HDAC3-IN-5 (9c) can effectively induce apoptosisin MV4-11 cells in vitro and reduce the expression of anti-apoptotic proteins, the development of HDAC3 selective inhibitors may serve as a potential lead compound to reverse Venetoclax resistance .
    HDAC3-IN-5
  • HY-176868
    Rodin-C

    		HDAC Neurological Disease
    Rodin-C is a selective HDAC inhibitor with IC50s of 0.059, 0.18   and 5.39 μM for HDAC1, HDAC2 and HDAC11, respectively, over HDAC3-10. Rodin-C significantly inhibits the HDAC-CoREST complex with low hematological toxicity. Rodin-C can be used for neurologic disorders such as Alzheimer’s disease research .
    Rodin-C
  • HY-157152
    HDAC-IN-65

    		HDAC Cancer
    HDAC-IN-65 ( compound 6) is a selective histone deacetylase (HDAC) inhibitor with IC50 value of 2.5μM. HDAC-IN-65 is a prodrug with very good bioreductive properties .
    HDAC-IN-65
  • HY-149529
    HDAC8-IN-5

    		HDAC Cancer
    HDAC8-IN-5 (Compound 6a) is a HDAC8 inhibitor (IC50: 28 nM). HDAC8-IN-5 can be used for cancer research .
    HDAC8-IN-5
  • HY-144102
    HDAC-IN-29

    		HDAC Cancer
    HDAC-IN-29 (compound 13b) is a potent pan-HDAC inhibitor. HDAC-IN-29 shows antitumor activity .
    HDAC-IN-29
  • HY-170966
    HDAC1-IN-9

    		HDAC Cancer
    HDAC1-IN-9 (13c) is a HDAC1 inhibitor. HDAC1-IN-9 inhibits HDAC1 enzyme with an IC50 of 1.07 µM. HDAC1-IN-9 exhibits the highest anti-proliferative effect against HT-29 (human colon adenocarcinoma), with anIC50 of 1.78 μM. HDAC1-IN-9 induces substantial Apoptosis in HCT-116 (human colon cancer) cells. HDAC1-IN-9 possesses antiangiogenic property. HDAC1-IN-9 reduces the expression levels of VEGFR-2 and phosphorylated VEGFR-2 (pVEGFR-2) by approximately 80 % .
    HDAC1-IN-9
  • HY-151897
    HDAC-IN-49

    		HDAC Cancer
    HDAC-IN-49 is a potent unselective HDAC (HDAC) inhibitor with IC50s of 13 nM, 14 nM, 21 nM, 1880 nM, and 10 nM for HDAC1, HDAC2, HDAC3, HDAC4, and HDAC6. HDAC-IN-49 demonstrates prominent antileukemic activity with low cytotoxic activity toward healthy cells .
    HDAC-IN-49
  • HY-157215
    HDAC-IN-66

    		HDAC Cancer
    HDAC-IN-66 (compound 2F) is a selective HDAC inhibitor and Pomalidomide (HY-10984) derivative that potently inhibits hematological tumor cells .
    HDAC-IN-66
  • HY-124559
    (Rac)-Nanatinostat

    (Rac)-CHR-3996

    		 HDAC Cancer
    (Rac)-Nanatinostat ((Rac)-CHR-3996, example 44) is a potent HDAC inhibitor with an IC50 of <330 nM. (Rac)-Nanatinostat has anticancer effects and can effectively inhibit the cell growth of HeLa, U937 and HUT cells .
    (Rac)-Nanatinostat
  • HY-117394
    MD 85

    		HDAC Cancer
    MD 85 is a potent histone deacetylase (HDAC) inhibitor with an EC50 of 5 μM. MD 85 can be used for cancer research .
    MD 85
  • HY-161984
    HDAC-IN-76

    		HDAC Infection Others
    HDAC-IN-76 (compound 6i) is a histone deacetylase (HDAC) inhibitor. HDAC-IN-76 IC50 values of 30 nM and 98 nM for Pf3D7 (chloroquine (HY-17589A) drug-susceptible strain) and PfDd2 (chloroquine (HY-17589A) drug-resistant strain), has a highly potent antimalarial activity against asexual blood-stage Plasmodium, respectively, and exhibits selective inhibition against parasites, with IC50 values of 7 nM and 9 nM for human HDAC1 and HDAC6, respectively, while inhibiting PfHDAC1 .
    HDAC-IN-76

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: